← All trials
NCT04468529
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2020
- Primary completion
- Dec 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jul 13, 2020
- Last posted
- Dec 2, 2020
- Enrollment
- 84
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ZensunLead sponsor
- Dalian Medical UniversityOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Shandong UniversityOverall official - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- China Three Gorges University, Yichang, ChinaOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Jinan UniversityOverall official - principal investigator
- Shengjing HospitalOverall official - principal investigator
- Haikou People's HospitalOverall official - principal investigator
- Luoyang Central HospitalOverall official - principal investigator
- Hainan People's HospitalOverall official - principal investigator
- Soochow UniversityOverall official - principal investigator
- Shandong Province Qianfoshan HospitalOverall official - principal investigator
- Shanghai Putuo District Central HospitalOverall official - principal investigator
- Shanxi cardiovascular hospitalOverall official - principal investigator
- Zhongshan Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.